Topic:

Europe

Latest Headlines

Latest Headlines

New group wants to attract pharma manufacturing to the U.K.

A new Medicines Manufacturing Industry Partnership has been jointly established by the Association of the British Pharmaceutical Industry and the BioIndustry Association.

Alzheimer's biotech Probiodrug plots a Euro IPO amid a continental boomlet

German drug developer Probiodrug is looking to go public on the Amsterdam exchange, seeking funds to advance its pipeline of treatments for Alzheimer's disease as more and more European biotechs set sights on IPOs.

EU IPOs: Up on '13, down on U.S., CRUK, MedImmune to run lab, Clal sues Hyperion

Welcome to the latest edition of our weekly  EuroBiotech Report.

Molecular Partners plots a $134M IPO for some R&D me-time

On the heels of some A-list biopharma partnerships, Switzerland's Molecular Partners is looking to double down on its in-house projects, swinging for a $134 million IPO to help pay its way.

Cubist makes Euro landfall with a $400M purse for antibiotics R&D

The antibiotics-focused Cubist Pharmaceuticals has opened up shop in Europe with a Swiss international headquarters, part of its plan to spend $400 million on infectious disease R&D this year and spotlight new treatments for global scourges.

Novo Nordisk wins EU approval for a diabetes combo with billion-dollar potential

Novo Nordisk picked up European approval for a combination of a long-acting insulin and its own Victoza, pioneering a once-a-day approach to Type 2 diabetes that could bring in blockbuster sales.

Dutch VC opens €65M cancer fund, Affimed IPO falls short, Evotec begins legal action

In this week's EuroBiotech Report, cash-starved European cancer startups had reason to cheer when Aglaia Biomedical Ventures revealed a new, €65 million ($84 million) oncology fund. The Dutch VC shop plans to invest the cash pool--which could rise to €100 million--in up to 15 early-stage biotechs. And more.

More counterfeits of Roche cancer drugs surface in Europe

Counterfeiters in Europe are displaying a fondness for mimicking high-priced Roche cancer drugs. For the second time in 5 months, authorities there have uncovered fakes, and the two cases appear not to be connected.

Hunt for next Sovaldi leads to $150M deal, Poxel raises €10M, AbbVie backs AM-Pharma round

In this week's EuroBiotech Report, the search for the drug that can do to hepatitis B what Sovaldi does to hepatitis C led OnCure BioPharma to Sweden to strike a $150 million (€116 million) deal with NeuroVive Pharmaceutical. And more.

Lilly and Boehringer snag EU nod for Lantus knockoff, but stateside hopes stay on ice

Eli Lilly and Boehringer Ingelheim won European clearance for their biosimilar of Lantus, Sanofi's top-selling insulin product, but the treatment's full potential remains hamstrung by a U.S. patent challenge.